Key result
Edoxaban was marginally superior to warfarin in reducing the risk of major adverse cardiac events in patients with atrial fibrillation.
Why the study?
Warfarin has long been standard anticoagulant therapy for AF but is limited by drug interactions and monitoring, while edoxaban has shown favorable bleeding outcomes.
Does edoxaban improve cardiovascular and bleeding outcomes compared to warfarin in patients with atrial fibrillation?
Meta-Analysis (n=26,832)
Does edoxaban improve cardiovascular and bleeding outcomes compared to warfarin in patients with atrial fibrillation?
Edoxaban demonstrates robust efficacy in reducing MACE and stroke/systemic embolism in atrial fibrillation, though warfarin may remain preferable in specific high-risk subgroups such as those with high CHA₂DS₂-VASc scores or significant heart failure.
Answers are grounded in this paper and cite their sources.
Edoxaban reduces MACE and SSE versus warfarin in AF; confirms overall benefit but leaves open optimal use in high CHA₂DS₂-VASc or prior MI subgroups.
Introduction Atrial fibrillation is the most prevalent cardiac arrhythmia in the United States and substantially increases the risk of stroke and heart failure in patients with non-valvular atrial fibrillation, those undergoing percutaneous coronary intervention, and transcatheter aortic valve repair. Warfarin, a vitamin K antagonist, has long been the standard anticoagulant therapy but is limited by drug interactions and monitoring requirements, while edoxaban, a factor Xa inhibitor, has shown favorable bleeding outcomes. Methods This meta-analysis included five randomized controlled trials identified through a comprehensive search of PubMed, Medline, Embase, Google Scholar, CENTRAL, and ClinicalTrials.gov from January 2014 to October 2024 (PROSPERO ID: CRD420250648890). Data were pooled using the inverse variance method with hazard ratios and 95% confidence intervals, DerSimonian–Laird random-effects model was applied in Stata version 17. Risk of bias was assessed using the Cochrane RoB v2 tool and certainty of evidence using GRADE assessment tool, with statistical significance set at P < 0.05. Results Edoxaban demonstrated a greater reduction in stroke or systemic embolism overall but was less effective in patients with prior myocardial infarction (HR 0.58, 95% CI 0.32–1.05). Major adverse cardiovascular events marginally favored edoxaban over warfarin (HR 0.90, 95% CI 0.83–0.98, P = 0.01), whereas warfarin performed better in patients with CHA₂DS₂-VASc scores ≥4. No significant difference was observed in all-cause mortality (P = 0.32). For clinically relevant non-major bleeding, warfarin was more favorable in patients aged ≥65 years and those with normal renal function, while edoxaban reduced major bleeding more effectively in patients with <25% heart failure; warfarin showed slight superiority when heart failure prevalence was ≥25%. Conclusion Overall, edoxaban shows robust efficacy across multiple outcomes, while warfarin remains essential in specific high-risk subgroups, warranting further confirmatory studies.
No takes yet. Share an insight, caveat, or question.
Sohail et al. (2025) conducted a meta-analysis in Atrial fibrillation (n=26,832). Edoxaban vs. Warfarin was evaluated on Major adverse cardiac events (MACE) (HR 0.90, 95% CI 0.83-0.97, p=0.01). Edoxaban was marginally superior to warfarin in reducing the risk of major adverse cardiac events in patients with atrial fibrillation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: